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ABSTRACT
Aims of this study were to investigate the ability of RACK1 pseudosubstrate alone 
or in combination with classical immune stimuli to activate human leukocytes, and to 
restore age-associated immune defects.
A total of 25 donors (17 old donors, 77–79 yrs; 8 young donors, 25–34 yrs) were 
enrolled. To evaluate the effect of RACK1 pseudosubstrate on cytokine production 
and CD86 expression the whole blood assay was used. Cultures were treated with 
RACK1 pseudosubstrate in the presence or absence of lipopolysaccharide (LPS) or 
phytohaemagglutinin (PHA) and incubated for 24 h or 48 h for LPS-induced CD86 
expression, TNF-α, IL-6, IL-8, IL-10 production, and PHA-induced IL-4, IL-10, IFN-γ, 
respectively. RACK1 pseudosubstrate alone induced IL-6, IL-8, and CD86 expression 
in both young and old donors, and IFN-γ in old donors. In combination with LPS 
an increase in IL-8, IL-10 and TNF-α was observed, also resulting in restoration 
of age-associated defective production, while no changes in the other parameters 
investigated were found.
Even if based on a small sample size, these results suggest the possibility to  
by-pass some of age-associated immune alterations, which may be beneficial in 
situations were natural immune stimulation is required, and highlight a different 
role of PKCβ in immune cells activation.
INTRODUCTION
Developed countries are experiencing an unprece­
dented increase in life expectancy that is accompanied 
by a rise in all age­associated problems, including 
immunosenescence and immuno­related disorders. 
Immunosenescence refers to the age­dependent changes 
responsible for the poor immune response to infections 
and the low efficacy of vaccination in elderly persons, 
which contributes to the enhanced rate of mortality and 
morbidity that are observed amongst the elderly [1]. 
Immunosenescence is characterized by a progressive 
deterioration of innate and adaptive immune functions, 
with immune cells displaying altered phenotype and 
function, thereby, providing an explanation for the clinical 
signs of immunosenescence [2–4].
In early studies aimed to characterize the molecular 
mechanisms underlying immunosenescence, we identified a 
defective protein kinase C (PKC) activation as a key player 
in the reduced response to immune stimulation. Specifically, 
we demonstrated that in the absence of a defect in total PKC 
expression, the failing element in its activation was the 
reduced expression of the Receptor for Activated C Kinase 1 
(RACK1), which underlies functional impairment associated 
with aging, including cytokine production, cell proliferation 
[5–8], and response to influenza vaccination [9].
RACK1 is a 36­kDa protein that contains seven 
WD-domain motifs and is related to G protein β subunits 
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[10, 11]. RACK1 is a highly conserved intracellular 
adaptor protein, which was originally identified as the 
anchoring protein for activated protein kinase C [12, 13]. 
In the past 20 years, the number of binding partners and 
validated cellular functions for RACK1 has increased, 
which is helping to define the versatile role of RACK1 in 
assembling and dismantling complex signaling pathways 
from the cell membrane to the nucleus in health and 
disease [14–16]. Relatively to PKC, RACK1 is able to 
interact preferentially with PKCβII [12] and PKCε [13], 
RACK1 modulates their activity by stabilizing their active 
conformation and promotes their translocation close 
to their specific substrates in order to activate defined 
pathways [10, 11]. PKCs play a key regulatory role in a 
variety of cellular functions, including cell growth and 
differentiation, gene expression, hormone secretion, etc. 
[17, 18]. Defective PKCβII translocation due to age-
associated RACK1 decline was described in different 
immune cells [19, 20], in rat brain [21] and also in skin 
cells [22]. More recently, investigating the role of RACK1 
and PKCβ in chemical allergen-induced CD86 expression 
and IL­8 production in the human promyelocytic cell 
line THP­1 and primary human dendritic cells, we 
demonstrated that a selective cell­permeable inhibitor of 
PKCβ completely prevented chemical allergen or LPS-
induced CD86 expression and significantly modulated 
IL­8 production (50% reduction). Furthermore, the use 
of a commercially available RACK1 pseudosubstrate, 
consisting of a peptide derived from the C2 domain of 
PKCβ designed to directly activate PKCβ and linked by 
a disulfide bridge to the Antennapedia domain vector 
peptide for a rapid cell uptake, resulted in dose­related 
increase in CD86 expression and IL­8 production [23], 
supporting a model where PKCβ activation is a key 
component of the signal transduction pathways that induce 
activation of dendritic cells.
Based on the important role of RACK1 and PKC in 
cellular physiology and immune cells activation together 
with its role in immunosenescence, the purpose of this study 
was to investigate the ability of RACK1 pseudosubstrate 
alone or in combination with classical immune stimuli 1) 
to activate leukocytes obtained from healthy young and old 
donors and 2) to restore some of the age­associated immune 
defects. Results obtained demonstrate the possibility to by­
pass some of the age­associated immune alterations by 
directly activating PKCβ, and overall highlight a different 
role of PKCβ activation in cytokine production.
RESULTS
Costimulatory effects of RACK-1 
pseudosubstrate on LPS-induced THP-1 cells 
activation
We have recently demonstrated a role of PKCβ 
and RACK1 in allergen­induced CD86 expression and 
IL­8 production in both THP­1 cells and primary human 
dendritic cells, supporting a central role of PKC-β in the 
initiation of antigen­induced dendritic cells activation 
[23]. To further support these findings, and to investigate 
possible costimulatory effects of RACK1 pseudosubstrate, 
we assessed its ability alone or in combination with LPS 
to induce IL-6, IL-8 and TNF-α production and CD86 
expression in THP­1 cells. As shown in Table 1, RACK1 
pseudosubstrate alone was able to induce IL­8 production 
and CD86 expression, confirming previous results, while 
at the concentration tested (2.5 μM) and time investigated 
(24 h), RACK1 pseudosubstrate alone failed to induce 
IL-6 or TNF-α production, suggesting that selective 
activation of PKCβ is not sufficient for the production of 
these cytokines. To study possible costimulatory effects, 
a suboptimal concentration of LPS (10 ng/ml) was used 
together with RACK1 pseudosubstrate. As expected, LPS 
alone induced a significant increase in CD86 expression 
and IL­8 production, while a modest production of IL­6 
and TNF-α was observed, indicative of a suboptimal 
concentration. The combination of LPS and RACK­1 
pseudosubstrate was associated for all parameters 
measured, with stastically significant higher production 
compared to cells treated with LPS alone, indicative of a 
costimulatory effect.
Table 1: Costimulatory effect of pseudoRACK1 on LPS-induced CD86 expression and cytokine 
production in THP-1 cells
TREATMENT CD86 (SI) IL-6 (pg/ml) IL-8 (pg/ml) TNF (pg/ml)
Control 1 5 ± 1 20 ± 3 14 ± 19
LPS 10 ng/ml 3.13 ± 0.10** 23 ± 4 3744 ± 687** 53 ± 4
pseudoRACK1 2.5 μM 1.59 ± 0.19* 6 ± 1 60 ± 16* 6 ± 11
LPS + pseudoRACK1 4.47 ± 0.44**, § 180 ± 27**, §§ 12713 ± 930**, §§ 139 ± 40**, §§
106/ml cells were treated with LPS, pseudoRACK1 or LPS + pseudoRACK1 for 24 h. Results are representative of three 
independent experiments. Means ± SD are shown, statistical analysis was performed with Tukey’s multiple comparison test 
with *p < 0.05 and **p < 0.01 vs control, and §§p ≤ 0.01 vs cells treated with LPS alone.
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These results de facto inspired the subsequent 
studies, the purpose of which was to evaluate in vitro the 
immunostimulatory effects of RACK1 pseudosubstrate 
using leukocytes obtained from young and old donors, 
with the ultimate goal of assessing the possibility to 
restore some of the immune deficiencies associated with 
aging.
Effects of RACK1 pseudosubstrate and LPS on 
leukocytes obtained from young and old donors
A total of 25 healthy subjects, 17 elderly (77–79 
years old, 7 women and 10 men) and 8 young (25–34 years 
old, 4 women and 4 men), were enrolled. Blood samples 
were taken on fasting early in the morning. In Table 2, the 
absolute and percentage count of leukocytes are reported. 
No statistically significant differences were observed 
among leukocytes betweeen young and old donors. This 
is important in light of the use of diluted whole­blood 
cultures. As all functional assays are carried out using the 
same amount of blood, it is essential to quantify both the 
relative and the absolute numbers of white blood cells. 
The use of whole blood may indeed mask some cytopenias 
or excess of a cell type, which may lead to false data 
interpretation.
Whereas studies using purified peripheral blood 
mononuclear cells or cell lines have provided substantial 
insight on mechanism underlying activation and cytokine 
production, they may be limited in their scope because 
they do not include all cell­cell or cell­protein interactions 
that take place in vivo, the whole blood assay serves as a 
useful bridge between in vivo situation and isolated cells 
[28, 29]. The whole blood assay is an easy to perform in 
vitro test that closely mimics the human situation. It is 
faster and cheaper than the more established peripheral 
blood mononuclear cell based assay, require less blood and 
saves material since no isolation of cells is required [30, 
31]. Consistently with our previous findings [7–9], aging 
was associated with a decrease in LPS-induced TNF-α 
production (Figure 1D and 1H, p < 0.01). In addition, 
a statistically significant reduced LPS-induced IL-6 
( p < 0.01), IL­8 ( p < 0.05) and IL­10 ( p < 0.01) production 
was also observed in leukocytes obtained from old donors 
compared to young donors (Figure 1). Consistently with 
results obtained in THP­1 cells, RACK1 pseudosubstrate 
alone was able to induce IL­8 production (Figure 1B and 
1F) and CD86 expression (Figure 2A and 2B) in both 
young and old donors. Contrary to THP­1 and young 
donors, in old donors RACK1 pseudosubstrate alone 
also induced a statistically significant production of IL-6 
(Figure 1E). In combination with LPS, a costimulatory 
effect was observed for LPS­induced IL­8 (Figure 1B 
and 1F) and IL­10 (Figure 1C and 1G) production in 
both young and old donors, for TNF-α (Figure 1H) in old 
donors and CD86 expression in young donors (Figure 2A). 
No costimulatory effects were observed for LPS­induced 
IL­6 production (Figure 1A and 1E). Importantly, in old 
donors RACK1 pseudosubstrate was able to completely 
restore LPS­induced IL­8 (Figure 1F) and IL­10 (Figure 
1G), and partially restore TNF-α (Figure 1H) production, 
which may be beneficial in situations were natural immune 
stimulation is required.
Effects of RACK1 pseudosubstrate and PHA on 
leukocytes obtained from young and old donors
In parallel, we explored the effect of RACK1 
pseudosubstrate alone or in combination with PHA on 
IL-4, IL-10 and IFN-γ production (Figure 3). Diluted 
whole blood cultures were exposed for 48 h with 
RACK1 pseudosubstrate alone or in combination with 
PHA. Consistently with our previous findings [9], aging 
was associated with an increase in PHA­induced IL­
10 production (Figure 3E, p < 0.01), while no change 
in IFN-γ was observed (Figure 3B and 3F). In addition 
to IL-10 and IFN-γ, we also measured the production 
of IL-4 and no changes in the production or in the IFN-γ/
IL­4 ratio were observed in the two groups (Figure 
3C, 3D and 3G, 3H). RACK1 pseudosubstrate alone 
had no effect on IL-4, IL-10 or IFN-γ production in 
leukocytes obtained from young donors (Figure 3A–3C), 
while a modest but statistically significant increase in 
IFN-γ production was observed in old donors at both 
concentrations tested (Figure 3F), which is also reflected 
in increased IFN-γ/IL-4 ratio in old donors (Figure 3H) 
compared to young donors (Figure 3D). In combination 
with PHA, the only relevant result was a significant 
reduction in the production of IL­10 in response to 
PHA in young donors (Figure 3A) and a similar trend in 
the elderly but not statistically significant (Figure 3B), 
Table 2: Absolute and differential count of leukocytes
GROUP WBC (103/μl) NE (%) LY (%) MO (%) EO (%) BA (%)
Young (n = 8) 7.09 ± 1.81 51.96 ± 8.04 34.70 ± 7.47 8.80 ± 2.20 4.14 ± 2.26 0.42 ± 0.22
Old (n = 17) 6.47 ± 1.25 54.28 ± 8.35 32.79 ± 8.57 8.67 ± 2.24 4.05 ± 2.65 0.63 ± 0.27
Each value represents mean ± SD. No statistically significant differences were found among age groups. WBC, white blood 
cells; NE, neutrphils; LY, lymphocytes; MO, monocytes; EO, eosinophils; BA, basophils.
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Figure 1: Effects of RACK1 pseudosubstrate alone or in combination with LPS on cytokine production in whole blood 
cultures. 1:10 diluted whole blood cultures obtained from young (left graph, n = 8) and old donors (right graph, n = 17) were treated 
or not with two concentrations of RACK1 pseudosubstrate (1 and 2.5 μM) in the presence or absence of LPS (10 ng/ml) for 24 h. (A, E) 
Effect on IL­6 production. (B, F) Effect on IL­8 production. (C, G) Effect on IL­10 production. (D, H) Effect on TNF-α production. Results 
are expressed mean ± SEM. Statistical analysis was performed with pair Student’s t test, with *p < 0.05 and **p < 0.01 vs control and 
§p < 0.05 and §§p < 0.01 vs LPS treated cultures.
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Figure 2: Effects of RACK1 pseudosubstrate alone or in combination with LPS on CD86 expression in whole blood 
cultures. 1:10 diluted whole blood cultures obtained from young and old donors were treated or not with two concentrations of RACK1 
pseudosubstrate (1 and 2.5 μM) in the presence or absence of LPS (10 ng/ml) for 24 h. (A) Effect on CD86 expression in young donors, 
n = 8. (B) Effect on CD86 expression in old donors, n = 17. Results are expressed mean ± SEM. Statistical analysis was performed with 
pair Student’s t test, with *p < 0.05 and **p < 0.01 vs control and §p < 0.05 and §§p < 0.01 vs LPS treated cultures.
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Figure 3: Effects of RACK1 pseudosubstrate alone or in combination with PHA on cytokine production in whole blood 
cultures. 1:10 diluted whole blood cultures obtained from young (left graph, n = 8) and old donors (right graph, n = 17) were treated or 
not with two concentrations of RACK1 pseudosubstrate (1 and 2.5 μM) in the presence or absence of PHA (3 μg/ml) for 48 h. (A, E) Effect 
on IL­10 production. (B, F) Effect on IFN-γ production. (C, G) Effect on IL­4 production. (D, H) Effect on IFN-γ/IL-4 ratio. Results are 
expressed mean ± SEM. Statistical analysis was performed with pair Student’s t test, with *p < 0.05 and **p < 0.01 vs control and §p < 
0.05 and §§p < 0.01 vs LPS treated cultures.
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together with a no dose-related increase in IFN-γ/IL-4 
ratio in the old donors (Figure 3H). These results are 
indicative of a minor role of PKCβ in PHA-induced IL-4, 
IL-10 and IFN-γ production.
DISCUSSION
The purpose of this study was to investigate the 
immunostimulatory effects of RACK1 pseudosubstrate 
in primary human leukocytes, with the ultimate goal of 
assessing the possibility to restore some of the immune 
defects associated with aging. Results showed that the 
direct activation of PKCβ using RACK1 pseudosubstrate, 
alone or in combination with classical immune activators, 
results in immune activation, as assessed by cytokine 
production, and in the revertion of some of the age­
associated immune dysfuntions.
The concentrations of 1 and 2.5 μM of RACK1 
pseudosubstrate were chosen from experiments in THP­
1 cells, where a clear dose response was observed [23]. 
For some of the parameters measured, using primary 
leukocytes, we did not observe a clear dose response. 
In particular we observed a better or similar stimulation 
with 1 μM compared to 2.5 μM. We can speculate that 
this maybe due to a different kinetic in the production of 
cytokines in response to a different vigor in cell activation 
following RACK pseudosubstrate stimulation or to donor 
variability that may level the response, or to a saturation 
in the ability of RACK1 pseudosubstrate to activate PKC 
in fresh leukocytes compared to cell lines.
It is widely accepted that aging is characterized by a 
pro-inflammatory imbalance termed ‘inflammaging’, with 
increased serum levels of inflammatory cytokines (TNF-α, 
IL-1, IL-6), while increased anti-inflammatory cytokines 
(IL-10, TGF-β) are possibly associated with more healthy 
aging [32]. In a previous unpublished study conducted in 
the same geographical area, which includes some of the 
same donors enrolled in the current study, we found in the 
elderly group increased serum levels of IL-1β (1.8 ± 1.9 
pg/ml vs 0.3 ± 1.0 pg/ml of the young group, p < 0.001. 
Results are expressed as mean ± SD, n = 20), TNF-α (23.9 
± 19.2 pg/ml vs 13.2 ± 42.1 pg/ml, p < 0.001) and IL­
10 (3.1 ± 2.0 pg/ml vs 1.5 ± 2.9 pg/ml, p < 0.01), and 
decreased levels of IL-1RA (69.4 ± 65.9 pg/ml vs 210.0 ± 
800.0 pg/ml, p < 0.05), consistent with literature data. In 
spite of this pro-inflammatory status, defective immune 
cells activation is observed when cells obtained from old 
donors are stimulated with classical immune activators 
[33]. In previous studies, using the whole blood assay, 
we found reduced TNF-α production in response to LPS, 
increased IL-10 and no change in IFN-γ production in 
response to PHA and decreased mitogen­induced T cell 
proliferation, which correlated with reduced leukocyte 
RACK1 expression [7–9]. No gender differences were 
observed. In the current study, the defective response 
to LPS was confirmed. Furthermore, not only TNF-α 
production in response to LPS was significantly reduced 
( p < 0.01) compared to young donors, but also IL­6, 
IL-8 and IL-10 were significantly reduced as well, 
indicating an overall reduction in monocyte activation. 
Such defective cytokine production in response to 
LPS, with the exception of IL­6, could be reversed by 
RACK1 pseudosubstrate. RACK1 pseudosubstrate di­
rectly activating PKCβ can by-pass the age-associated 
reduced RACK1 expression, and restore PKC­mediated 
cell activation. The costimulatory effect of RACK1 
pseudosubstrate on LPS­induced IL­6 production 
observed in THP-1 cells could not be confirmed in primary 
cells obtained from both young and old donors. Overall, 
THP­1 cells are a good model to assess monocyte/
macrophage functions, but they do not completely reflect 
the response of primary human cells. Concerning the 
activation of T cells, RACK1 pseudosubstrate alone 
had no effect on IL-4, IL-10 or IFN-γ production in 
leukocytes obtained from young donors, while a modest 
but statistically significant increase in IFN-γ production 
was observed in old donors. In combination with PHA, 
the only relevant result was a significant reduction in the 
production of IL­10 in response to PHA in young donors. 
A similar inhibitory effect on IL­10 production was also 
observed using in the young donors anti CD3/CD28 as 
stimuli (data not shown), no data are currently available 
on old donors. A slight reduction in IL­10 production 
was observed in the elderly, but it was not statistically 
significant. The concentration of PHA was selected using 
leukocytes obtained from young donors, in the case of 
IL­10, where old donors produce much higher levels, a 
lower concentration of PHA may be necessary to observe 
a modulation. Further studies are clearly necessary to 
characterize its specific role in T cell activation, including 
proliferation and T cell migration. Overall, these results 
are indicative of a minor role of PKCβ in PHA-induced 
IL-4, IL-10 and IFN-γ production.
It is well known that PKCs play a key regulatory 
role in a variety of cellular functions, including cell 
growth and differentiation, gene expression, hormone 
secretion, etc. [18–20, 34]; PKC family is the largest 
serine/threonine-specific kinase family known to 
comprise approximately 2% of the human kinome [35]. 
It is also clear that different PKCs are not functionally 
redundant, for example specific PKCs mediate specific 
cellular signals required for activation, proliferation, 
differentiation and survival of immune cells [36–39], and 
patterns of expression for each PKC isoform differ among 
tissues [18]. Of the classical PKCs isoforms, only PKC­
βII was consistently activated during DC-differentiation-
inducing stimuli in normal and leukemic progenitors 
[40]. PKC-βII activation by cytokines (GM-CSF + IL-4 + 
TNF-α) in DC was demonstrated to be associated to up-
regulation of DC surface markers (MHCI and MHCII, 
CD11c, CD40, CD80, CD86 and CD83), the induction 
of expression of the NF-κB family member c-Rel, and 
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the ability to stimulate allogeneic T cell proliferation. 
Our findings support a model where PKCβ activation 
is a key component of the signal transduction pathways 
that induce CD86 up­regulation and IL­8 production in 
monocyte/macrophage activation following exposure to 
LPS. On the contrary its role in T cell activation seems 
to be less prominent. This is consistent with data that 
highlight a central role of other PKC isoforms, namely 
PKCθ, PKCε and PKCα, in antigen receptor-mediated 
T cell activation ex vivo and T cell­mediated immunity 
in vivo [39]. In T cells, however, a role of PKCβ in T cell 
locomotion has been demonstrated, where T cells crowling 
has been shown to be associated with the translocation of 
PKCβ to the microtubule cytoskeleton [41]. Alterations 
in PKC expression and/or function may have important 
implications in health and disease and warrants a detailed 
investigation into the downstream target genes and the 
underlying mechanisms involved [42–45]. Further work 
is needed to identify mechanisms underlying PKCs 
recruitment or exclusion, potential redundancy, and 
relevance during immune cells activation.
With the limitation of being a small sample size study, 
nevertheless our findings contribute to the understanding 
of the mechanism underlying immunosenescence. The 
significant results obtained, although with the need 
of confirmation in larger cohort of subjects, open the 
possibility to use the selective activation of specific 
PKC isoforms to provide novel therapeutic strategies 
to manipulate monocyte activation and to counteract 
immunosenescence. As the effectiveness of vaccines is 
reduced in older versus younger adults because of age­
related immunosenescence, the use of an adjuvant, such 
as RACK1 pseudosubstrate, may represent a strategy that 
may combat immunosenescence, potentially by boostering 
dendritic cells activation and T­cell mediated responses, 
resulting in a more effective response to vaccination. 
Development of drugs that target the PKCβ pathway may 
lead to novel therapeutic options for treating age­related 
disease including immunosenescence.
METHODS
Chemicals
Lipopolysaccharide from Escherichia coli serotype 
0127:B8 was obtained from Sigma (St Louis, MO, 
USA); phytohaemagglutinin was from Invitrogen (PHA, 
Invitrogen, Paisley, UK). All reagents were purchased at 
the highest purity available.
Experiments with THP-1 cells
THP-1 cells (Istituto Zooprofilattico di Brescia, 
Italy) were diluted to 106 cells/mL in RPMI 1640 
containing 2 mM L­glutamine, 0.1 mg/mL streptomycin, 
100 IU/mL penicillin, 50 μM 2-mercaptoethanol, 
supplemented with 10% heated­inactivated foetal calf 
serum (media) and cultured at 37°C in 5% CO2 incubator.
To investigate the role of PKCβ in THP-1 
activation, a pseudo RACK1 activator of protein 
kinase C was used (Tocris Bioscience, Bristol UK). 
The pseudosubstrate consists of a peptide derived from 
the C2 domain of PKC-β (24) linked by a disulfide 
bridge to the Antennapedia domain vector peptide. The 
sequence of the peptide, as reported from the supplier, is: 
KKWKMRRNQFWIKIQRC CSVEIWD* (Modifications: 
disulfide bridge between 17–1*). The Antennapedia 
peptide is actively taken up by intact cells, ensuring 
rapid and effective uptake of the activator peptide [25]. 
Once inside the cell, the disulfide bonds are subjected to 
reduction in the cytoplasm leading to production of the 
activator peptide. Cells were treated with concentrations 
and times specified in the legends.
To investigate the co­stimulatory effect of RACK1 
pseudosubstrate, cells were treated simultaneously with 
the pseudosubstrate in the presence or absence of LPS 
(10 ng/ml).
Study population
In this study a total of 25 healthy subjects living 
in the same geographical area of Northern Italy were 
recruited. These subjects included 17 elderly subject 
(age range 77–79; 7 women and 10 men) and 8 young 
subjects (age range 25–34, 4 women and 4 men). All 
elderly subjects were community dwelling, functionally 
independent and participating to the InVeCe Ab population 
based study [26]. Healthy subjects were selected according 
to the guidelines of the Italian Health authorities and to 
the Declaration of Helsinki principles and signed an 
informed consent. Criteria for exclusion were the presence 
of abnormal laboratory values (i.e. altered hemocrome) or 
the use of medication known to affect the immune system, 
i.e. steroids, or patients suffering from malignancies, 
inflammations and infections.
Preparation of whole blood cells and cytokine 
production
Blood samples were taken by venous puncture with 
sodium citrate 0.5 M as anticoagulant. Sodium citrate was 
chosen instead of heparin or EDTA as anticoagulant, since 
functional assays were performed using the whole blood 
assay and heparin may be contaminated with endotoxin, 
while EDTA interferes with cell activation. Blood samples 
were diluted 1:10 in cell culture medium RPMI 1640 
(Sigma, St Louis, USA) containing 2 mM L­glutamine, 
0.1 mg/ml streptomycin, 100 IU/ml penicillin. Diluted 
blood samples were treated in the presence or absence of 
LPS at final concentration of 10 ng/ml or PHA 0.3 μg/ml 
and incubated for 24 h or 48 h at 37°C in a humidified 5% 
CO2 incubator for TNF-α, IL-6, IL-8, IL-10, and IL-4, IL-10 
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and IFN-γ production, respectively. Owing to the variability 
in stimulation assays, the same lot of each reagent was used 
in all experimental cultures. The suboptimal concentration 
of LPS and PHA were chosen in preliminary dose­response 
experiments. The use of suboptimal concentrations allow to 
highlight any costimulatory effects. Cell­free supernatants 
obtained by centrifugation at 1200 rpm for 5 min were 
stored at −20°C until measurement.
Cytokine production
Cytokine production was assessed in cell free 
supernatants by a specific sandwich ELISA, commercially 
available (R&D System, Minneapolis, MN, USA). Results 
are expressed in pg/ml.
Flow cytometric analysis of CD86 expression
CD86 expression was evaluated as previously 
described [27]. Briefly, after 24 h of treatment, THP-
1 cells were centrifuged, washed once with cold PBS 
and suspended in PBS supplemented with 1% FCS and 
0.1% NaN3. 10
5 cells were stained in the dark for 30 min 
for THP­1 cells or 15 minutes for blood samples with 
specific FITC-conjugates antibodies against CD86 (BD 
Biosciences) or with isotype control antibody at room 
temperature (BD Biosciences). 1 ml of PBS was then 
added and cells centrifuged at 1200 rpm for 5 min and 
resuspended in 0.5 ml of PBS supplemented with 1% 
FCS and 0.1% NaN3. For the blood samples, after 24 h 
of treatment, dliluted whole blood was centrifuged at 1500 
rpm for 5 min and pellets resuspended in 100 μl of PBS 
supplemented with 0.1% NaN3, 50 μl was stained in the 
dark for 15 minutes with the specific antibodies or with 
isotype control antibody at room temperature. 1 ml of 
FACS lysing solution (BD Biosciences) was then added 
and samples incubated for 10 min, then centrifuged 
at 1200 rpm for 10 min and resuspended in 0.5 ml of 
PBS supplemented with 0.1% NaN3. The intensity of 
fluorescence and the percentage of positive cells were 
analyzed using a FACSCalibur flow cytometer and 
data were quantified using CellQuest software (Becton 
Dickinson). 10,000 viable cells were analyzed for mean 
fluorescence intensity (MFI) and percentage of positive 
cells (PC). All experiments were performed in triplicate.
Changes in CD86 expression are reported as 
stimulation index (SI) calculated by the following equation:
PCt and MFIt stand for treated cells, whereas PCc 
and MFIc for the untreated ones.
Statistical analysis
All experiments using THP­1 were repeated at least 
three times, with representative results shown. Statistical 
analysis was performed using GraphPad InStat version 
3.0a for Macintosh (GraphPad Software, San Diego, CA, 
USA). For multiple comparisons analysis of variance was 
used with Tukey post­hoc test. For blood samples, pair 
Student’s t test was used. Differences were considered 
significant at p ≤ 0.05.
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Summary sentence
Results demonstrate the possibility to by­pass some 
of the age­associated immune alterations, and highlight a 
different role of PKC-β in immune cells activation.
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